Overview

Clinical Study of Palivizumab in Japanese Newborns, Infants and Young Children at the Age of 24 Months or Less With Immunocompromised Medical Conditions

Status:
Completed

Trial end date:
2012-04-01

Target enrollment:

Participant gender:

Summary

To evaluate safety, efficacy and pharmacokinetics of palivizumab in children at the age of 24 months or less with immunocompromised medical conditions.

Phase:

Phase 3

Details

Lead Sponsor:

AbbVie (prior sponsor, Abbott)

Treatments:

Palivizumab